CRISPR Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

CRISPR Therapeutics kazanç ve gelirin sırasıyla yıllık 34.5% ve 54.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 35.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -9.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

34.5%

Kazanç büyüme oranı

35.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	54.3%
Gelecekteki özkaynak getirisi	-9.5%
Analist kapsamı	Good
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BRSE:1CG - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	559	-262	-294	-269	16
12/31/2025	138	-446	-370	-347	26
12/31/2024	15	-431	-182	-149	25
9/30/2024	203	-240	-191	-189	N/A
6/30/2024	202	-266	-129	-122	N/A
3/31/2024	272	-217	-169	-159	N/A
12/31/2023	371	-154	-272	-260	N/A
9/30/2023	170	-354	-295	-278	N/A
6/30/2023	170	-416	-362	-343	N/A
3/31/2023	100	-524	-377	-352	N/A
12/31/2022	1	-650	-533	-496	N/A
9/30/2022	14	-681	-509	-468	N/A
6/30/2022	15	-633	-516	-445	N/A
3/31/2022	915	312	414	504	N/A
12/31/2021	915	378	457	539	N/A
9/30/2021	902	412	465	544	N/A
6/30/2021	902	447	502	549	N/A
3/31/2021	1	-392	-309	-287	N/A
12/31/2020	1	-349	-257	-238	N/A
9/30/2020	77	-211	-167	-154	N/A
6/30/2020	289	20	45	55	N/A
3/31/2020	289	46	40	48	N/A
12/31/2019	290	67	50	57	N/A
9/30/2019	213	-11	18	25	N/A
6/30/2019	1	-200	-133	-128	N/A
3/31/2019	2	-185	-121	-117	N/A
12/31/2018	3	-165	-99	-96	N/A
9/30/2018	35	-117	-85	-83	N/A
6/30/2018	37	-91	N/A	-79	N/A
3/31/2018	40	-75	N/A	-69	N/A
12/31/2017	41	-68	N/A	-70	N/A
9/30/2017	11	-51	N/A	-75	N/A
6/30/2017	10	-41	N/A	-71	N/A
3/31/2017	7	-36	N/A	-69	N/A
12/31/2016	5	-23	N/A	-53	N/A
9/30/2016	3	-53	N/A	33	N/A
6/30/2016	2	-44	N/A	40	N/A
3/31/2016	1	-31	N/A	51	N/A
12/31/2015	0	-26	N/A	59	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1CG önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 1CG önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 1CG önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 1CG şirketinin gelirinin (yıllık 54.3% ) Swiss pazarından (yıllık 4.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1CG şirketinin gelirinin (yıllık 54.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1CG 3 yıl içinde kârsız olması bekleniyor.

CRISPR Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin